Progress in Immunization Safety Monitoring - Worldwide, 2020-2022

• Published in: MMWR. Morbidity and mortality weekly report Vol. 72; no. 49; pp. 1321 - 1326
• Main Authors: Blau, Erin F, Balakrishnan, Madhava Ram, Sköld, Helena, Santhana Gopala Krishnan, Ravi Shankar, Lundquist, Pinelopi, Pal, Shanthi, Gidudu, Jane F
• Format: Journal Article Newsletter
• Language: English
• Published: United States U.S. Government Printing Office 08.12.2023; U.S. Center for Disease Control; Centers for Disease Control and Prevention
• Subjects: Adverse Drug Reaction Reporting Systems; Collaboration; Complications and side effects; COVID-19 Vaccines; Full Report; Humans; Immunization; Immunization - adverse effects; Public health; Regions; Regulatory agencies; Safety; Safety and security measures; Surveillance; Vaccination; Vaccination - adverse effects; Vaccines; Vaccines - adverse effects
• ISSN: 0149-2195; 1545-861X
• DOI: 10.15585/MMWR.MM7249A2

Effective surveillance of adverse events following immunization (AEFIs) primarily relies on the collaboration of two partners: national regulatory authorities (NRAs) and national expanded programs on immunization (EPIs). In December 2020, the World Health Organization (WHO) Global Advisory Committee for Vaccine Safety recommended a new case-based indicator of national capacity to monitor immunization safety: at least one serious AEFI reported per 1 million total population per year. To achieve this indicator, WHO-affiliated countries and territories (WHO countries) rely upon data generated from functional AEFI surveillance systems. This report describes 2020-2022 global, regional, and national progress in use of the newly introduced immunization safety monitoring indicator and progress on joint AEFI reporting from national EPIs and NRAs. Among WHO countries, 51 (24%) of 214 implemented the new indicator in 2020, 111 (52%) of 214 implemented it in 2021, and 92 (43%) of 215 in 2022. In 2020, 41 (19%) WHO countries reported AEFI data jointly from EPIs and NRAs; this increased to 55 (26%) in 2021 and 57 (27%) in 2022. These findings, resulting in part from the intensified support for COVID-19 vaccination, demonstrate that national AEFI surveillance systems increasingly support the timely use and sharing of case-based immunization safety data, but work is still needed to strengthen global vaccine safety monitoring.